We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cardiovascular safety trials: Be careful what you wish for (心血管安全性研究:当心你许的愿).
- Authors
Bloomgarden, Zachary; Grunberger, George
- Abstract
The authors reflect on two trials of the dipeptidyl peptidase (DPP)-4 inhibitors alogliptin and saxagliptin. The authors state that the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) involved 5380 patients with diabetes who had recent acute coronary syndrome. They add that 8280 type 2 diabetics were randomized to saxagliptin and 8212 to placebo in the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) trial.
- Subjects
CLINICAL trials; CD26 antigen; TYPE 2 diabetes treatment; PEOPLE with diabetes; RANDOMIZED controlled trials; PLACEBOS
- Publication
Journal of Diabetes, 2014, Vol 6, Issue 1, p1
- ISSN
1753-0393
- Publication type
Article
- DOI
10.1111/1753-0407.12092